Published in Drug Week, April 28th, 2006
Study 1: Scientists are investigating the use of a strategy of HIV treatment interruption based on CD4+ cell counts.
Researchers in Italy conducted a study to "evaluate the safety of treatment interruption (TI) guided by CD4+ count in HIV-infected patients followed-up prospectively."
A. Boschi and colleagues at AUSL Rimini explained, "Patients on HAART with a CD4+ cell count >500 cells/mm3 discontinued therapy with instructions to start therapy again before their CD4+ count dropped below 200 cells/mm3. We...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.